Randomized Clinical Trial on the Long-Term Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1Sally A. Hulton, John C. Lieske, David J. Sas et al.|Kidney International Reports|2021Cited by 32
Intrafamilial Disease Heterogeneity in Primary Hyperoxaluria Type 1Lisa J. Deesker, Bodo B. Beck, Hazal A. Karacoban et al.|Kidney International Reports|2024Cited by 5
12-Month Analysis of ILLUMINATE-A, a Phase 3 Study of Lumasiran: Sustained Oxalate Lowering and Kidney Stone Event Rates in Primary Hyperoxaluria Type 1Jeffrey M. Saland, John C. Lieske, Jaap W. Groothoff et al.|Journal of the American Society of Nephrology|2020Cited by 4
MO047STABLE EGFR IN PATIENTS WITH PRIMARY HYPEROXALURIA TYPE 1 TREATED WITH LUMASIRAN, REGARDLESS OF KIDNEY FUNCTION AT START OF TREATMENTWesley Hayes, Yaacov Frishberg, Sander F. Garrelfs et al.|Nephrology Dialysis Transplantation|2021Cited by 0
DFGe stable chez les patients atteints d’hyperoxalurie primitive de type 1 sous lumasiran, indépendamment de la fonction rénale au début du traitementWesley Hayes, Yaacov Frishberg, Sander F. Garrelfs et al.|Néphrologie & Thérapeutique|2021Cited by 0